ArticleCancer research2021
Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model.
Abstract readValidation Study
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 7 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Risk prediction for lung cancer screening: a systematic review and meta-regression.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Development and validation of a multiancestry and multitrait polygenic risk score for lung cancer.Nature communications · 2026Pooled it
- Genome-wide meta-analysis across East Asian and European populations provides insights into the molecular basis of lung cancer.Genome medicine · 2026Pooled it
- The current state of polygenic scores for the development of lung cancer: a systematic review and validation in UK Biobank.British journal of cancer · 2026Pooled it
- A systematic review and meta-analysis of lung cancer risk prediction models.Acta oncologica (Stockholm, Sweden) · 2025Pooled it
- Predictive performance of risk prediction models for lung cancer incidence in Western and Asian countries: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Genetic Analysis of Lung Cancer and the Germline Impact on Somatic Mutation Burden.Journal of the National Cancer Institute · 2022Pooled it
- Allostatic load, genetic susceptibility, and lung cancer risk: Evidence from a prospective cohort and integrative proteomic analyses.PLOS digital health · 2026Article
- Biological aging and generational shifts in early-onset cancer risk.Nature medicine · 2026Article
- Performance validation and clinical concordance of a novel fully automated immunoassay system for five tumor markers: A comparative study with an international reference platform.Practical laboratory medicine · 2026Article
- Clinical usefulness of polygenic risk scores in risk prediction models for lung cancer screening and lung nodule management.Translational oncology · 2026Article
- Genome wide association analysis and association of genetic risk and lifestyle with upper gastrointestinal cancer among an endoscopy-screened cohort in China.Science bulletin · 2026Article
- Polygenic risk scores: Navigating the future of precision medicine through economic, ethical, and scientific advancements.iScience · 2026Review
- Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Review
- Advancing liver cancer diagnosis and treatment with multi-omics approaches: a systematic review.Discover oncology · 2025Review
- Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers.Journal of the National Cancer Institute · 2025Article
- Stratifying Lung Adenocarcinoma Risk with Multi-ancestry Polygenic Risk Scores in East Asian Never-Smokers.medRxiv : the preprint server for health sciences · 2025Article
- Effect of Long-Term Fine Particulate Matter Exposure on Lung Cancer Incidence and Mortality in Chinese Nonsmokers.American journal of respiratory and critical care medicine · 2025Article
- Cancer incidence inconsistency between UK Biobank participants and the population: a prospective cohort study.BMC medicine · 2025Article
- Plant-based dietary patterns, genetic risk, proteome, and lung cancer risk: a large prospective cohort study.European journal of nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Rayjean J HungLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada. rayjean.hung@lunenfeld.ca.ORCID 0000-0002-4486-7496
Matthew T Warkentin *Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.ORCID 0000-0001-8730-3511
Yonathan Brhane *Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.
Nilanjan ChatterjeeDepartment of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
David C ChristianiDepartment of Environmental Health, Harvard TH Chan School of Public Health, and Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-0301-0242
Maria Teresa LandiDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
Neil E CaporasoDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
Geoffrey LiuPrincess Margaret Cancer Center, Toronto, Canada.ORCID 0000-0002-2603-7296
Mattias JohanssonInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0002-3116-5081
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
Loic Le MarchandUniversity of Hawaii Cancer Center, Honolulu, Hawaii.
Adonina TardonUniversidad de Oviedo, ISPA and CIBERESP, Oviedo, Spain.ORCID 0000-0001-5150-1209
Gad RennertDepartment of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Stig E BojesenHerlev and Gentofte Hospital, Copenhagen, Denmark. Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Chu ChenFred Hutchinson Cancer Research Center, Seattle, Washington.
John K FieldUniversity of Liverpool Cancer Research Centre, Liverpool, United Kingdom.ORCID 0000-0003-3951-6365
Lambertus A KiemeneyRadboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.ORCID 0000-0002-2368-1326
Philip LazarusWashington State University, Spokane, Washington.
Shanbeth ZienolddinyNational Institute of Occupational Health, Oslo, Norway.
Stephen LamUniversity of British Columbia, Vancouver, Canada.
Angeline S AndrewDartmouth Medical School, Hanover, New Hampshire.
Susanne M ArnoldMarkey Cancer Center, Lexington, Kentucky.
Melinda C AldrichDepartment of Thoracic Surgery, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0003-3833-8448
Heike BickeböllerDepartment of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany.
Angela RischUniversity of Salzburg and Cancer Cluster Salzburg, Salzburg, Austria.ORCID 0000-0002-8026-5505
Matthew B SchabathH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0003-3241-3216
James D McKayInternational Agency for Research on Cancer, Lyon, France.
Paul BrennanInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0002-0518-8714
Christopher I AmosInstitute for Clinical and Translational Research, Baylor Medical College, Houston, Texas.ORCID 0000-0002-8540-7023
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MUniversity of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3MUnderstanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4MTranslating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos · 2017 to 2026
$23.7MGENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2MTHE ROLE OF CAL IN CIF-MEDIATED DEGRADATION OF CFTRP20RR018787 · NCRR · DARTMOUTH COLLEGE · PI GERBER, SCOTT · 2003 to 2011
$21.9MVALIDATION OF A DIET HISTORY METHOD FOR EPIDEMIOLOGIC STUDIES OF CANCERP01CA033619 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 1985 to 2010
$18.5MKentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3MTHE CAROTENE AND RETINOL EFFICACY TRIAL (CARET)U01CA063673 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 1994 to 2006
$13.0MThe Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2MTranslational studies of Hsp90 inhibitors in NSCLCP50CA090578 · NCI · DANA-FARBER CANCER INST · PI YEAP, BEOW Y · 2008 to 2012
$11.4MMedical Research Council MC_PC_17228Medical Research Council MC_QA137853NCATS NIH HHS UL1 TR000117NCATS NIH HHS UL1 TR000445NCI NIH HHS K07 CA172294NCI NIH HHS P01 CA033619NCI NIH HHS P20 CA090578NCI NIH HHS P30 CA076292NCI NIH HHS P30 CA177558NCI NIH HHS P50 CA090578NCI NIH HHS P50 CA119997NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA074386NCI NIH HHS R01 CA092824NCI NIH HHS R35 CA197449NCI NIH HHS U01 CA063464NCI NIH HHS U01 CA063673NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA167462NCI NIH HHS U01 CA209414NCI NIH HHS U19 CA148127NCI NIH HHS U19 CA203654NCI NIH HHS UM1 CA164973NCI NIH HHS UM1 CA167462NCRR NIH HHS P20 RR018787NCRR NIH HHS S10 RR025141World Health Organization 001
Abstract
Lung cancer is the leading cause of cancer-related death globally. An improved risk stratification strategy can increase efficiency of low-dose CT (LDCT) screening. Here we assessed whether individual's genetic background has clinical utility for risk stratification in the context of LDCT screening. On the basis of 13,119 patients with lung cancer and 10,008 controls with European ancestry in the International Lung Cancer Consortium, we constructed a polygenic risk score (PRS) via 10-fold cross-validation with regularized penalized regression. The performance of risk model integrating PRS, including calibration and ability to discriminate, was assessed using UK Biobank data (
Indexed as
Models, GeneticMultifactorial InheritanceAdultAgedAge FactorsBiomarkers, TumorCase-Control StudiesEarly Detection of CancerFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansIncidenceLungLung NeoplasmsMachine LearningBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.